Complete report details @ https://www.wiseguyreports.com/reports/649779-trigeminal-neuralgia-pipeline-review-h2-2016
Summary
‘Trigeminal Neuralgia - Pipeline Review, H2 2016’, provides an
overview of the Trigeminal Neuralgia pipeline landscape.
The report provides comprehensive information on the
therapeutics under development for Trigeminal Neuralgia, complete with analysis
by stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally, the
report provides an overview of key players involved in therapeutic development
for Trigeminal Neuralgia and features dormant and discontinued projects.
Report features investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000 indications. The report is built using
data and information sourced from
proprietary databases, company/university websites, clinical trial
registries, conferences, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third party
sources. Drug profiles featured in the report undergoes periodic review following
a stringent set of processes to ensure that all the profiles are updated with
the latest set of information. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in
the market and their portfolios, enhances decision making capabilities and
helps to create effective counter strategies to gain competitive advantage.
Request a sample report @ https://www.wiseguyreports.com/sample-request/649779-trigeminal-neuralgia-pipeline-review-h2-2016
Scope
- The report provides a snapshot of the global therapeutic landscape
of Trigeminal Neuralgia
- The report reviews pipeline therapeutics for Trigeminal Neuralgia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Trigeminal Neuralgia therapeutics and enlists all their major and minor projects
- The report assesses Trigeminal Neuralgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Trigeminal Neuralgia
- The report reviews pipeline therapeutics for Trigeminal Neuralgia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Trigeminal Neuralgia therapeutics and enlists all their major and minor projects
- The report assesses Trigeminal Neuralgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Trigeminal Neuralgia
Make an enquiry before buying this Report @
https://www.wiseguyreports.com/enquiry/649779-trigeminal-neuralgia-pipeline-review-h2-2016
Reasons
to buy
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Trigeminal Neuralgia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Trigeminal Neuralgia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Trigeminal Neuralgia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Trigeminal Neuralgia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Check Discount on this report @ https://www.wiseguyreports.com/check-discount/649779-trigeminal-neuralgia-pipeline-review-h2-2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Trigeminal Neuralgia Overview 7
Therapeutics Development 8
Pipeline Products for Trigeminal Neuralgia - Overview 8
Pipeline Products for Trigeminal Neuralgia - Comparative Analysis 9
Trigeminal Neuralgia - Therapeutics under Development by Companies 10
Trigeminal Neuralgia - Therapeutics under Investigation by Universities/Institutes 11
Trigeminal Neuralgia - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Trigeminal Neuralgia - Products under Development by Companies 15
Trigeminal Neuralgia - Products under Investigation by Universities/Institutes 16
Trigeminal Neuralgia - Companies Involved in Therapeutics Development 17
Allergan Plc 17
Biogen Inc 18
KPI Therapeutics, Inc. 19
Merz Pharma GmbH & Co. KgaA 20
Trigemina, Inc. 21
Trigeminal Neuralgia - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
(clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
incobotulinumtoxin A - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
NeuroRelease TN - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
onabotulinumtoxin A - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
oxytocin - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
raxatrigine hydrochloride - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
U-2902 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Trigeminal Neuralgia - Dormant Projects 51
Trigeminal Neuralgia - Product Development Milestones 52
Featured News & Press Releases 52
Jun 27, 2016: PixarBio Promotes David Kaplan to Chief Commercial Officer, as NeuroRelease a Morphine Strength Non Addictive Pain Treatment Remains on Track for 2018 Launch 52
Mar 30, 2016: PixarBio, the Developers of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President of External Affairs 53
Mar 03, 2016: PixarBio's Dr. Taunia Markvicka and Glenn Reiser to Discuss Breakthrough Data on Morphine Strength Non-Addictive Pain Treatment NeuroRelease at the 2016 Congress of Neurological Surgeons Spine Summit held in Orlando, FL March 17-18, 2016 53
Nov 30, 2015: PixarBio's Glenn Reiser to Present Data on NeuroRelease, a Breakthrough Non-opiate and Non-addictive Pain Platform, at the 2015 Life Sciences Summit in New York, NY 54
Oct 26, 2015: PixarBio Announces USFDA OPD Submission of NeuroRelease TN for Orphan Drug Designation for Trigeminal Neuralgia 54
Sep 23, 2014: Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy 55
Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study 55
Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802 56
Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study 57
Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802 57
Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Trigeminal Neuralgia Overview 7
Therapeutics Development 8
Pipeline Products for Trigeminal Neuralgia - Overview 8
Pipeline Products for Trigeminal Neuralgia - Comparative Analysis 9
Trigeminal Neuralgia - Therapeutics under Development by Companies 10
Trigeminal Neuralgia - Therapeutics under Investigation by Universities/Institutes 11
Trigeminal Neuralgia - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Trigeminal Neuralgia - Products under Development by Companies 15
Trigeminal Neuralgia - Products under Investigation by Universities/Institutes 16
Trigeminal Neuralgia - Companies Involved in Therapeutics Development 17
Allergan Plc 17
Biogen Inc 18
KPI Therapeutics, Inc. 19
Merz Pharma GmbH & Co. KgaA 20
Trigemina, Inc. 21
Trigeminal Neuralgia - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
(clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
incobotulinumtoxin A - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
NeuroRelease TN - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
onabotulinumtoxin A - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
oxytocin - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
raxatrigine hydrochloride - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
U-2902 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Trigeminal Neuralgia - Dormant Projects 51
Trigeminal Neuralgia - Product Development Milestones 52
Featured News & Press Releases 52
Jun 27, 2016: PixarBio Promotes David Kaplan to Chief Commercial Officer, as NeuroRelease a Morphine Strength Non Addictive Pain Treatment Remains on Track for 2018 Launch 52
Mar 30, 2016: PixarBio, the Developers of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President of External Affairs 53
Mar 03, 2016: PixarBio's Dr. Taunia Markvicka and Glenn Reiser to Discuss Breakthrough Data on Morphine Strength Non-Addictive Pain Treatment NeuroRelease at the 2016 Congress of Neurological Surgeons Spine Summit held in Orlando, FL March 17-18, 2016 53
Nov 30, 2015: PixarBio's Glenn Reiser to Present Data on NeuroRelease, a Breakthrough Non-opiate and Non-addictive Pain Platform, at the 2015 Life Sciences Summit in New York, NY 54
Oct 26, 2015: PixarBio Announces USFDA OPD Submission of NeuroRelease TN for Orphan Drug Designation for Trigeminal Neuralgia 54
Sep 23, 2014: Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy 55
Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study 55
Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802 56
Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study 57
Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802 57
Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60
Check Discount on this report @ https://www.wiseguyreports.com/check-discount/649779-trigeminal-neuralgia-pipeline-review-h2-2016
Contact US:
NORAH TRENT
Partner Relations
& Marketing Manager
sales@wiseguyreports.com
Ph:
+1-646-845-9349 (US)
Ph:
+44 208 133 9349 (UK)
No comments:
Post a Comment